OFFICIAL PUBLICATION OF

by its subsidiary APPco

MSD melanoma drug listed

Megan Haggan 20/04/2015

melanoma: dermatologist examines mole on woman's shoulder

A new treatment for advanced melanoma which has seen significant media attention is now available in Australia. MSD announced that its anti-PD1 immunotherapy KEYTRUDA (pembrolizumab) has been registered by the TGA for the treatment of the most deadly form of skin cancer – advanced melanoma. The treatment has been the subject of a Change.org petition

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Recent Comments
Popular Posts

Review backs same job, same pay

Genuine question. Are we offering the same service? I'm not sure how GPs claim from Medicare but if I see…

John Smith

ACCC approval could take time for Sigma, CWH merger

Come on Paul, we're pharmacists here, you're not trying to convince a bunch of people that don't understand our industry.…

John Smith

Escape the city for better pay

This has literally always been the case and it is the case across most professions. Obviously employers need to pay…

Greg Cadorin

CAPS leaders to contest Guild elections

I think you're giving CAPS a lot of credit here. The Labor government has really dropped the ball since it…

John Smith

MSD melanoma drug listed

Previous Council urges Aussies to consider bowel cancer

Next TGA upgrades eBusiness website

Clinical tips: Timing!

Clinical tips: Movement disorders

Clinical tips: Worms, Worms, Worms

Intranasal Midazolam for at home use

MENU

Previous Council urges Aussies to consider bowel cancer

Next TGA upgrades eBusiness website

Related Posts

MENU

Hi there! 👋 Looks like you’re not logged in.